PCSK9 and diabetes mellitus: This was confirmed by observations in different models of diabetes, e.g., liver insulin receptor knockout (LIRKO) rodents, ob/ob mice treated with insulin receptor—IR antisense oligonucleotides—ASO (IR ASO) or mice after streptozotocin (STZ) injection, all of which were characterized by decreased levels of Pcsk9.